What were the results of the PROVE IT-TIMI 22 study regarding the impact of baseline LDL cholesterol on the benefit of intensive lipid-lowering therapy?
The PROVE IT-TIMI 22 study found that baseline low-density lipoprotein cholesterol was an important predictor of the benefit of intensive lipid-lowering therapy. Patients with lower LDL cholesterol levels at baseline were found to benefit most from intensive lipid-lowering therapy.